Trader consensus leans slightly against Eli Lilly signing a commercial license for Peptron's SmartDepot sustained-release peptide platform by October 7, with "No" at 52% implied probability, reflecting Lilly's pivot to oral obesity drugs like orforglipron and competing partnerships such as Camurus's fluidcrystal depot and PepLib Biotech's peptide collaboration. The initial October 2024 non-exclusive evaluation agreement has been extended through December 2025 to October 2026, but repeated delays and Lilly's $20B+ in 2026 licensing deals elsewhere have eroded optimism, causing Peptron stock volatility. Key swing factors include evaluation data readouts or termination signals; upcoming catalysts like Lilly's Q2 earnings or pre-deadline announcements could tip the closely contested odds.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhậtMỚI
MỚI
Oct 7, 2026
MỚI
MỚI
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Trader consensus leans slightly against Eli Lilly signing a commercial license for Peptron's SmartDepot sustained-release peptide platform by October 7, with "No" at 52% implied probability, reflecting Lilly's pivot to oral obesity drugs like orforglipron and competing partnerships such as Camurus's fluidcrystal depot and PepLib Biotech's peptide collaboration. The initial October 2024 non-exclusive evaluation agreement has been extended through December 2025 to October 2026, but repeated delays and Lilly's $20B+ in 2026 licensing deals elsewhere have eroded optimism, causing Peptron stock volatility. Key swing factors include evaluation data readouts or termination signals; upcoming catalysts like Lilly's Q2 earnings or pre-deadline announcements could tip the closely contested odds.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Thị trường mở: May 5, 2026, 8:02 PM ET
Khối lượng
$8,097Ngày kết thúc
Oct 7, 2026Thị trường mở
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Trader consensus leans slightly against Eli Lilly signing a commercial license for Peptron's SmartDepot sustained-release peptide platform by October 7, with "No" at 52% implied probability, reflecting Lilly's pivot to oral obesity drugs like orforglipron and competing partnerships such as Camurus's fluidcrystal depot and PepLib Biotech's peptide collaboration. The initial October 2024 non-exclusive evaluation agreement has been extended through December 2025 to October 2026, but repeated delays and Lilly's $20B+ in 2026 licensing deals elsewhere have eroded optimism, causing Peptron stock volatility. Key swing factors include evaluation data readouts or termination signals; upcoming catalysts like Lilly's Q2 earnings or pre-deadline announcements could tip the closely contested odds.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Khối lượng
$8,097Ngày kết thúc
Oct 7, 2026Thị trường mở
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Trader consensus leans slightly against Eli Lilly signing a commercial license for Peptron's SmartDepot sustained-release peptide platform by October 7, with "No" at 52% implied probability, reflecting Lilly's pivot to oral obesity drugs like orforglipron and competing partnerships such as Camurus's fluidcrystal depot and PepLib Biotech's peptide collaboration. The initial October 2024 non-exclusive evaluation agreement has been extended through December 2025 to October 2026, but repeated delays and Lilly's $20B+ in 2026 licensing deals elsewhere have eroded optimism, causing Peptron stock volatility. Key swing factors include evaluation data readouts or termination signals; upcoming catalysts like Lilly's Q2 earnings or pre-deadline announcements could tip the closely contested odds.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp